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Rapamycin and its derivatives are mTOR inhibitors
used in tissue transplantation and cancer therapy.
A percentage of patients treated with these
inhibitors develop diabetic-like symptoms, but the
molecular mechanisms are unknown. We show
here that chronic rapamycin treatment in mice led
to insulin resistance with suppression of insulin/
IGF signaling and genes associated within this
pathway, such as Igf1-2, Irs1-2, and Akt1-3. Impor-
tantly, skeletal muscle-specific YY1 knockout mice
were protected from rapamycin-induced diabetic-
like symptoms. This protection was caused by hy-
peractivation of insulin/IGF signaling with increased
gene expression in this cascade that, in contrast
to wild-type mice, was not suppressed by rapa-
mycin. Mechanistically, rapamycin induced YY1
dephosphorylation and recruitment to promoters of
insulin/IGF genes, which promoted interaction with
the polycomb protein-2 corepressor. This was
associated with H3K27 trimethylation leading to
decreased gene expression and insulin signaling.
These results have implications for rapamycin action
in human diseases and biological processes such as
longevity.
INTRODUCTION
mTOR is a serine/threonine protein kinase that receives inputs
from multiple signals, such as growth factors and nutrients,
and plays a central role in the regulation of cell growth, size,
and survival (Sengupta et al., 2010b). mTOR is part of two protein
complexes, named mTORC1 and mTORC2. A specific compo-
nent of mTORC1 is Raptor, which is required for most of the
signaling that controls protein synthesis and metabolism (Ging-
ras et al., 2004; Polak and Hall, 2009). Rictor, which is part of
mTORC2, is involved in cytoskeleton dynamics and feedback
signaling to AKT (Jacinto et al., 2004; Sarbassov et al., 2005).CDownstream effectors of mTORC1 regulate protein synthesis
by phosphorylating key translational regulators, such as
ribosomal S6 kinase (S6K) and eukaryotic initiation factor 4E
binding protein (Dowling et al., 2010; Fingar et al., 2002; Sen-
gupta et al., 2010b). Rapamycin is a small molecule that binds
to FKBP12 and specifically inhibits mTORC1 activity by
changing its conformation and preventing substrate binding
(Kim et al., 2002; Sabatini et al., 1994; Yip et al., 2010). The bio-
logical activities of this drug, including the effects on life span,
are driven through inhibition of mTOR (Bjedov et al., 2010;
Harrison et al., 2009; Schieke and Finkel, 2006). In humans,
rapamycin is a drug commonly prescribed to suppress the
immune system in patients after solid organ transplantation
(Monaco, 2009), and rapamycin analogs are currently in clinical
trials for treatment of several cancers and tuberous sclerosis
complex disease (Guertin and Sabatini, 2007; Meric-Bernstam
and Gonzalez-Angulo, 2009; Petroulakis et al., 2006; Plas
and Thomas, 2009; Sampson, 2009). Importantly, contrary to
what would be predicted based on the mTOR-activated S6K
negative feedback on insulin signaling (Haruta et al., 2000;
Sarbassov et al., 2005; Um et al., 2004), a percentage of
patients treated with mTOR inhibitors develop a variety of
diabetic-like symptoms, including glucose intolerance, insulin
resistance, and dyslipidemia (Bodziak and Hricik, 2009; Cole
et al., 2008; Johnston et al., 2008; Roland et al., 2008). Interest-
ingly, some of these metabolic defects have also been observed
in rodent models treated with rapamycin (Fraenkel et al., 2008;
Houde et al., 2010), but the molecular mechanisms and
target tissues by which this drug causes prodiabetic effects
are unknown.
Although upstream mechanisms and proteins regulating
mTOR have been elucidated in detail (Hay and Sonenberg,
2004), its downstream effectors, particularly those regulating
transcription, are not completely understood. mTOR controls
lipid biosynthesis by modulating SREBP-1 and its target
genes (Brown et al., 2007; Du¨vel et al., 2010; Mauvoisin et al.,
2007; Peng et al., 2002; Porstmann et al., 2008). Furthermore,
mTOR regulates glycolysis through hypoxia-inducible factor 1
alpha (HIF1a) (Du¨vel et al., 2010) and ketogenesis through perox-
isome proliferator-activated receptor alpha (PPARa), possibly
by regulating subcellular localization of the corepressor NCoR1
(Sengupta et al., 2010a). Moreover, our previous workell Metabolism 15, 505–517, April 4, 2012 ª2012 Elsevier Inc. 505
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through the transcription factor Yin Yang 1 (YY1) and the tran-
scriptional coactivator peroxisome proliferator-activated recep-
tor gamma coactivator-1 alpha (PGC1a) (Cunningham et al.,
2007). However, whether and how transcriptional regulatory
mechanisms are involved in the rapamycin-induced diabetic-
like effects on glucose and lipid metabolism and insulin action
is unknown.
Here we show that chronic inhibition of mTOR by rapamycin
led to insulin resistance and lipid dysregulation associated
with defective insulin/IGF signaling and suppression of key
genes of this pathway, such as Igf1-2, Irs1-2, and Akt1-3.
Importantly, skeletal muscle-specific YY1 knockout (YY1mKO)
mice were protected against the rapamycin-induced diabetic-
like effects including insulin resistance, dyslipidemia, and
suppression of insulin signaling. YY1mKOmice exhibited hyper-
activation of insulin/IGF signaling and increased expression
of the genes of this pathway. In contrast to wild-type mice,
rapamycin did not suppress insulin/IGF signaling genes in
YY1mKO mice. Upon rapamycin treatment YY1 functioned as
a transcriptional repressor of insulin signaling genes through
interaction with the polycomb protein Pc2 and recruitment at
the promoters of these genes, which was associated with
H3K27 trimethylation. Moreover, mTOR regulated the interac-
tion between YY1 and Pc2 through YY1 phosphorylation at
T30 and S365. In summary, we show that YY1 mediates sup-
pression of insulin signaling genes through polycomb proteins
and epigenetic changes in response to mTOR inhibition, and
this accounts, at least in part, for the prodiabetic effects of rapa-
mycin in vivo.
RESULTS
Chronic Rapamycin Treatment in Mice Causes Insulin
Resistance and Lipid Dysregulation
Given the clinical relevance of rapamycin-induced diabetic
effects, we used an experimental mouse model to investigate
the underlying molecular mechanisms. Figure 1 shows that
mice treated for 2 weeks with rapamycin developed significant
glucose intolerance (Figure 1A) and decreased insulin sensitivity
(Figure 1B), as measured by glucose and insulin tolerance tests.
These parameters correlatedwith changes inHOMA-IR (Homeo-
stasis Model Assessment of Insulin Resistance), a surrogate of
insulin sensitivity (Figure S1A). Interestingly, these metabolic
effects were detected, albeit to a lesser magnitude, with a single
dose of rapamycin (Figure S1B). Moreover, mice chronically
treated with rapamycin displayed hyperinsulinemia without
changes in the insulin/C-peptide ratio (Figure 1C). To determine
the tissues involved in the rapamycin-inducedwhole-body insulin
resistance, we performed hyperinsulinemic-euglycemic clamps
(Figures S1C and S1D). Rapamycin-treated mice required
lower glucose infusion rates tomaintain bloodglucose compared
to vehicle-treated mice (Figure 1D). These effects were linked to
decreases in glucose disposal in different tissues, including
skeletal muscle (Figure 1E). Hepatic insulin resistance was also
observed in rapamycin-treated mice, as detected by augmented
endogenous glucose production measured in the clamp experi-
ments (Figure S1E). Consistent with the clinical side effects of
mTOR inhibitors in humans, mice treated with rapamycin dis-506 Cell Metabolism 15, 505–517, April 4, 2012 ª2012 Elsevier Inc.played hypertriglyceridemia and hypercholesterolemia (Fig-
ure 1F). Furthermore, increased intracellular lipids in skeletal
muscle (Figure 1G), which are often associated with insulin
resistance (Erion and Shulman, 2010; Savage et al., 2007), were
detected in mice treated with rapamycin. In these conditions,
rapamycin did not affect the ability of the pancreas to secrete
insulin, as assessed by blood insulin levels after glucose admin-
istration by oral gavage (Figure S1F). Interestingly, all these
metabolic changes were observed in the absence of significant
differences in body weight (Figure S2A); adiposity, as analyzed
by MRI (Figure S2B); or food intake (Figure S2C). These results
indicate that chronic rapamycin treatment in mice, similar to
humans, causes whole-body insulin resistance associated
with dyslipidemia and accumulation of lipids in skeletal muscle.
Moreover, these data suggest that skeletal muscle plays a
major role in the development of rapamycin-induced diabetic
symptoms.
Next, we tested whether the metabolic effects of rapamycin in
mice were occurring specifically throughmTORC1 using skeletal
muscle-specific Raptor knockout mice (RamKO) (Bentzinger
et al., 2008) and a different mTOR chemical inhibitor, Torin 2
(Liu et al., 2011). RamKO mice were resistant to the rapamycin
metabolic effects on glucose tolerance (Figure S2D) and
increases in intramyocellular triglycerides (Figure S2E). In addi-
tion, chronic treatment with Torin 2 also caused glucose intoler-
ance, though the effects were not as pronounced as with
rapamycin (Figure S2F), suggesting different efficacies of these
inhibitors and/or independent mTORC2 contributions. As pre-
dicted, these results suggest that rapamycin causes prodiabetic
symptoms in mice through mTOR.
Chronic Rapamycin Treatment Decreases Insulin
Signaling in Skeletal Muscle and Liver
In order to determine whether rapamycin-induced insulin resis-
tance correlated with defects in insulin signaling, we analyzed
phosphorylation of different components of this transduction
pathway as an index of activity. Consistent with whole-body
insulin resistance and reduction in glucose disposal in
skeletal muscle, rapamycin significantly decreased insulin-
stimulated phosphorylation of the insulin receptor, IRS1, AKT,
and downstream targets involved in both glucose uptake
(AS160) and insulin-dependent gene expression (FoxO1) (Fig-
ure 2A). The decrease in phosphorylation of insulin signaling
proteins correlated in some cases with a reduced protein level,
including IRS1, IRS2, and AKT1-3. A similar pattern of defective
insulin signaling was detected in liver (Figure 2B), which could
account for the hepatic insulin resistance and increased rates
of hepatic glucose production detected by hyperinsulinemic-
euglycemic clamps in mice treated with rapamycin (Figure S1E).
Consistent with the decreased insulin-stimulated signaling and
levels of different proteins in this pathway, rapamycin treatment
significantly repressed expression of the genes encoding for
these proteins. Specifically, Igf1-2, Irs1-2, and Akt1-3 mRNA
levels were significantly lower in skeletal muscle of rapamy-
cin-treated mice (Figure 2C). These results indicate that chronic
rapamycin treatment in mice causes resistance to insulin
signaling and action and represses insulin signaling gene
expression, which is reflected in the reduction of their protein
levels.
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Figure 1. Chronic Rapamycin Treatment Causes Insulin Resistance and Lipid Dysregulation
(A–G) Mice were treated with vehicle or 2.5 mg/kg rapamycin for 14 days. Shown are: glucose tolerance test (A), insulin tolerance test (B), serum insulin level and
insulin/C-peptide ratio (C), glucose infusion rate during hyperinsulinemic-euglycemic clamps (D), glucose uptake rate under basal and clamp condition and index
of tissue glucose uptake (Rg) (E), serum triglycerides and cholesterol (F), and intramyocellular triglycerides (G). All values are presented as mean ± SD, n = 6–10,
*p < 0.05, **p < 0.01, and ***p < 0.001. See also Figures S1 and S2.
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YY1 Regulates Insulin Signaling in Skeletal MuscleSkeletal Muscle-Specific YY1 Knockout Mice Are
Protected from Rapamycin-Induced Diabetic-like
Effects
We have previously identified the transcription factor YY1 as
part of the transcriptional response regulated by mTOR (Cun-
ningham et al., 2007). Because one of the major metabolic
effects of rapamycin is decreased insulin-dependent peripheral
glucose disposal that largely occurs in skeletal muscle (Fig-
ure 1E), we generated a skeletal muscle-specific YY1 knockout
mouse (YY1mKO) to determine whether YY1 mediates the dia-Cbetic-like symptoms induced by rapamycin in vivo. To this
purpose we crossed a floxed YY1 allele (Affar et al., 2006)
with a muscle-specific myogenin CRE driver (Li et al., 2005)
to generate YY1mKO mice. Yy1 mRNA levels were almost
undetectable in skeletal muscle, but were not decreased in
other tissues such as liver or white or brown fat (Figure S3A).
YY1mKO mice were born at a normal Mendelian ratio, and
their body weight was comparable to their wild-type
littermates (Figure S3B). Notably, these mice showed improved
glucose tolerance and insulin sensitivity compared to theirell Metabolism 15, 505–517, April 4, 2012 ª2012 Elsevier Inc. 507
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Figure 2. Chronic Rapamycin Treatment
Decreases Insulin Signaling in Skeletal
Muscle and Liver
(A–C) Mice were treated with vehicle or 2.5 mg/kg
rapamycin for 14 days, fasted for 12 hr, and then
injected with vehicle or 0.6 U/kg insulin 10 min
before sacrifice. Insulin signaling in skeletal
muscle (A) and liver (B) are shown. Also shown is
gene expression in the soleus from fedmice (C). All
values are presented as mean ± SD, n = 6–10,
*p < 0.05, and **p < 0.01.
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YY1 Regulates Insulin Signaling in Skeletal Musclewild-type littermates (Figures 3A and 3B). Importantly, Figures
3C and 3D show that while control mice (fl/fl) treated with
rapamycin developed glucose intolerance and insulin re-
sistance, YY1mKO mice (cre-fl/fl) were protected and displayed
glucose and insulin tolerance curves similar to vehicle-treated
YY1mKO mice. Moreover, YY1mKO mice were also pro-
tected from increases in serum levels of cholesterol and triglyc-
erides (Figure 3E), insulin (Figure 3F), and intramyocellular
triglycerides (Figure 3G) caused by chronic rapamycin treat-
ment. Interestingly, serum triglycerides were not increased in
YY1mKO mice upon rapamycin treatment, but basal levels
were higher in these mice compared to wild-type littermates.
This is in agreement with the observation that YY1mKO mice508 Cell Metabolism 15, 505–517, April 4, 2012 ª2012 Elsevier Inc.have decreased expression of fatty
acid oxidation genes in skeletal muscle
(S.M.B. and P.P., unpublished data).
These data indicate that skeletal muscle
YY1 is required for the development of
diabetic-like symptoms caused by rapa-
mycin in mice.
Skeletal Muscle-Specific YY1
Knockout Mice Display
Hyperactivation of Insulin/IGF
Signaling and Increased Gene
Expression that Are Insensitive
to Rapamycin
Although YY1mKOmice were resistant to
rapamycin-induced glucose intolerance,
insulin resistance, hyperinsulinemia, and
hyperlipidemia, it still remained unclear
whether YY1 directly mediated the
rapamycin-induced diabetic symptoms
by targeting core components of the
insulin/IGF signaling cascade. We there-
fore investigated whether differences
existed in insulin/IGF signaling activity in
YY1mKO mice. Interestingly, Figure 4A
shows that when compared to wild-type
mice, vehicle-treated YY1mKO mice
displayed increased basal and insulin-
stimulated phosphorylation of AKT and
downstream components of the insulin/
IGF signaling, such as AS160, FoxO1,
GSK3, and ribosomal S6. Remarkably,
in contrast to wild-type mice that havedecreased insulin-stimulated phospho-AKT in the presence of
rapamycin, YY1mKO mice responded similarly to insulin in the
presence and absence of rapamycin (Figure 4A). This insulin sig-
naling pattern is consistent with the rapamycin-induced meta-
bolic effects observed in glucose and insulin tolerance tests
(Figures 3C and 3D). Next, we further analyzed additional
components of the insulin/IGF signaling in YY1mKO mice in
response to insulin stimulation. YY1mKO mice exhibited in-
creased insulin-induced phosphorylation of the IGF1 and
insulin receptors; AKT, mTOR, S6K, and S6 ribosomal proteins;
and downstream targets such as FoxO1, GSK3, and AS160
(Figure 4B). Notably, we found that levels of some of these
proteins, especially IRS1, IRS2, and AKT1-3, were strongly
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Figure 3. Skeletal Muscle-Specific YY1 Knockout Mice Are Protected from Rapamycin-Induced Diabetic-like Effects
(A and B) Glucose tolerance test (A) and insulin tolerance test (B) in YY1mKO mice or wild-type littermates.
(C–G) Wild-type or YY1mKOmice were treated with vehicle or 2.5 mg/kg rapamycin for 14 days. Shown are: glucose tolerance test (C), insulin tolerance test (D),
serum cholesterol and triglycerides (E), serum insulin levels (F), and intramyocellular triglycerides (G). All values are presented as mean ± SD, n = 6–10, *p < 0.05,
**p < 0.01, and ***p < 0.001. See also Figure S3.
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that YY1 might control expression of these insulin/IGF signaling
proteins at the transcriptional level. It further suggests that YY1
could mediate the rapamycin suppressive effects on the
signaling genes observed in wild-type mice. To test this, we
measured expression of different genes involved in this
pathway in wild-type and YY1mKO mice. Consistent with the
metabolic and signaling parameters, Figure 4C shows that
YY1mKO mice have increased expression of insulin/IGF sig-
naling genes such as Igf1, Igf2, Irs1, Irs2, and Akt1-3, indicating
that YY1 mediates transcriptional repression on these genes
in vivo. Importantly, rapamycin did not repress skeletal muscleCgene expression of these transcripts related to insulin/IGF
signaling in YY1mKO mice, suggesting that YY1 is required for
rapamycin-mediated suppression effects on these genes (Fig-
ure 4C). These data indicate that increased expression of selec-
tive insulin signaling genes and their insensitivity to repression by
rapamycin in YY1mKO mice could account for the protection
against rapamycin-induced diabetic-like symptoms.
We next determined whether the effects of YY1 on insulin/IGF
signaling gene expression were cell autonomous by using YY1
shRNA (Figure S4A) and YY1 overexpression (Figure S4B) in
C2C12 myotubes. Depletion of YY1 mimicked the gene expres-
sion effects observed in YY1mKO mice (Figure 4D), whereasell Metabolism 15, 505–517, April 4, 2012 ª2012 Elsevier Inc. 509
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Figure 4. Skeletal Muscle-Specific YY1 Knockout Mice Display Hyperactivation of Insulin/IGF Signaling and Increased Gene Expression that
Are Insensitive to Rapamycin Treatment
(A and B) Wild-type or YY1mKO mice were treated for 14 days with vehicle or 2.5 mg/kg rapamycin, fasted for 12 hr, and then injected with vehicle or 0.6 U/kg
insulin 10 min before sacrifice. Insulin signaling in skeletal muscle is shown.
(C) Wild-type or YY1mKO mice were treated with vehicle or 2.5 mg/kg rapamycin for 14 days and gene expression in the soleus of fed mice was measured.
(D) Gene expression in C2C12 myotubes infected with scrambled shRNA or YY1 shRNA for 72 hr.
(E) Gene expression in C2C12 myotubes infected with GFP or Flag-YY1 for 48 hr. All values are presented as mean ± SD, n = 6–10, *p < 0.05, **p < 0.01, and
***p < 0.001. See also Figure S4.
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YY1 Regulates Insulin Signaling in Skeletal MuscleYY1 overexpression decreased the levels of insulin/IGF signaling
genes (Figure 4E). These experiments show that modulation of
YY1 affects insulin/IGF signaling gene expression in vivo, leading510 Cell Metabolism 15, 505–517, April 4, 2012 ª2012 Elsevier Inc.to dysregulated protein expression and, consequently, signaling.
Furthermore, our experiments show that the effect of YY1 on
these genes is cell autonomous.
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Figure 5. Rapamycin Suppresses Insulin/IGF Signaling Genes by Promoting Interaction between YY1 and the Polycomb Corepressor Pc2
(A) Coimmunoprecipitation and western blot analysis in HEK293 cells.
(B) YY1 protein cartoon.
(C) Coimmunoprecipitation and western blot analysis in HEK293 cells.
(D) Luciferase assay in HEK293 cells with a Gal4-YY1 luciferase construct and the indicated polycomb proteins.
(E) Coimmunoprecipitation of HA-YY1 and Flag-Pc2 in HEK293 cells treated with vehicle or rapamycin (20 nM) for 2 hr.
(F) Endogenous interaction between YY1 and Pc2 was detected in skeletal muscle from mice treated with vehicle or 2.5 mg/kg rapamycin for 2 hr.
(G) Gene expression in C2C12 myotubes infected with GFP or Flag-Pc2 for 48 hr.
(H) Coimmunoprecipitation and western blot analysis of HEK293 cells treated with vehicle or rapamycin (20 nM) for 2 hr.
(I) Gene expression in C2C12 myotubes infected with GFP, wild-type YY1, YY1-AA, or YY1–DD for 48 hr. All values are presented as mean ± SD, n = 6, *p < 0.05,
**p < 0.01, and ***p < 0.001. See also Figures S5 and S6.
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Promoting Interaction between YY1 and the Polycomb
Corepressor Pc2
We have previously shown that YY1 physically interacts with
mTORC1 (Cunningham et al., 2007), although the YY1 domains
involved in this interaction were unknown. To mechanisticallyCinvestigate how rapamycin controls YY1 transcriptional activity
and represses insulin signaling gene expression, the Raptor
(a component of the mTORC1 complex)-specific interaction
domain on YY1 was mapped. Figure 5A shows that Raptor spe-
cifically interacted with the REPO (REcruitment of POlycomb)
domain of YY1 (Figure 5B). Since Raptor is known to bind toell Metabolism 15, 505–517, April 4, 2012 ª2012 Elsevier Inc. 511
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Blenis, 2002), we searched the REPO domain of YY1 to deter-
mine if this was the mode of binding. Figure 5C shows that
when the conserved phenylalanine of a putative TOS motif in
YY1 (Figure S5A) is mutated to alanine, binding between YY1
and Raptor is abolished. Since the YY1 REPO domain is respon-
sible for recruiting polycomb group proteins to DNA in Dros-
ophila (Wilkinson et al., 2006), we hypothesized that changes in
mTORC1 activity could be associated with docking of polycomb
corepressors to YY1 as a mechanism to suppress expression of
target genes. For this reason, we first tested whether any of the
mammalian polycomb group proteins could affect YY1 tran-
scriptional activity. By using a luciferase-based Gal4-YY1 tran-
scriptional assay, several of the polycomb homologs (and one
HP homolog, Cbx5) were screened to determine which, if any,
control YY1 activity. Figure 5D shows that, of all the mammalian
polycomb homologs, only Pc2/Cbx4 was able to significantly
repress YY1 transcriptional activity. In addition, the activity of
Gal4-YY1 was inhibited by treatment with rapamycin (Figure 5D,
right panel). These results suggested that Pc2-mediated repres-
sion could be associated with its binding to YY1 and possibly be
regulated by mTORC1 activity. Indeed, the binding of Pc2 to
YY1 was strongly dependent upon mTORC1 activity, as Pc2, in
contrast to other YY1 corepressors such as CtBP1 (Figure S5B),
was recruited to YY1 upon rapamycin treatment in HEK293 cells
(Figure 5E). Notably, rapamycin promoted the interaction
between endogenous YY1 and Pc2 in mouse skeletal muscle
(Figure 5F). Consistent with these data, ectopic expression of
Pc2 in C2C12 myotubes (Figure S5C) mimicked rapamycin treat-
ment on insulin signaling gene expression (Figure 5G). These
results indicate that inactivation of mTORC1 leads to Pc2 func-
tioning as a negative regulator of YY1 transcriptional activity
through direct physical recruitment, providing a molecular basis
by which rapamycin represses YY1 target gene expression.
Our observations that YY1 binds constitutively to mTORC1
through the REPO domain and that rapamycin leads to suppres-
sion of YY1 target gene expression suggested that YY1 phos-
phorylation might be involved in this transcriptional regulatory
mechanism. We therefore tested whether mTORC1 activity
could affect YY1 phosphorylation status using a combination
of qualitative and semiquantitative analyses with mass spec-
trometry. As detailed in Supplemental Experimental Procedures,
the qualitative analysis of digested YY1 peptides led to the
detection of phospho-T30 and phosho-S365 only in YY1 immu-
noprecipitated from cells treated with vehicle, but these two
residues were not detected phosphorylated in YY1 immu-
noprecipitated from cells treated with rapamycin. Interestingly,
in semiquantitative analysis peptide amounts containing
phospho-T30 were significantly less abundant in YY1 from
rapamycin-treated cells (Figures S5D–S5G). Because mTORC1
inactivation resulted in decreased phosphorylation of YY1,
we next determined whether T30 and S365 phosphorylation
could modulate the physical interaction with Pc2. The double
T30A/S365A YY1 mutant (YY1-AA) showed selectively enriched
interaction with Pc2 that, in contrast to wild-type YY1, was not
increased by rapamycin (Figure 5H), suggesting that dephos-
phorylation at both sites is needed for efficient Pc2 recruitment
after rapamycin treatment. In fact, the phosphomimetic T30D/
S365D YY1 mutant (YY1-DD) did not bind to Pc2 efficiently (Fig-512 Cell Metabolism 15, 505–517, April 4, 2012 ª2012 Elsevier Inc.ure 5H), further supporting that phosphorylation of these two
residues mediates the interaction between YY1 and Pc2. In
keeping with the effects of YY1- and rapamycin/Pc2-dependent
suppression of insulin/IGF signaling genes, the proximal region
of the IRS2 promoter fused to luciferase was strongly repressed
by YY1 overexpression as well as by rapamycin (Figure S6A). In
addition, the YY1-AA mutant, which mimics the dephosphoryla-
tion of YY1 induced by rapamycin, inhibited IRS2 promoter-
driven luciferase expression to a greater extent than wild-type
YY1. Overexpression of Pc2 further increased the repression of
both YY1 wild-type and YY1-AA mutant. Notably, YY1-AA
mutant was insensitive to rapamycin. Similar effects were also
observed using YY1 alleles on endogenous insulin/IGF signaling
genes in C2C12 myotubes. In fact, YY1 dephospho-mimetic
mutant acted as a potent suppressor of these genes compared
to YY1 wild-type or YY1 phospho-mimetic mutant (Figure 5I and
Figure S6B). Together, these results indicate that rapamycin
controls the physical interaction between YY1 and Pc2 core-
pressor through phosphorylation of YY1 residues T30 and
S365 and leads to transcriptional repression of YY1 targeted
insulin/IGF signaling genes.
Rapamycin Induces Recruitment of YY1 and Pc2
to Promoters of Insulin/IGF Signaling Genes Associated
with H3K27 Trimethylation
Although modulation of YY1 expression and rapamycin treat-
ment affected insulin/IGF signaling gene expression in skeletal
muscle, it remained unclear if YY1 is able to bind directly to the
promoters of these genes. For this reason, we decided to
perform chromatin immunoprecipitation (ChIP) analysis on
skeletal muscle from vehicle- and rapamycin-treated mice. Fig-
ure 6 shows that recruitment of YY1 (Figure 6A) and Pc2 (Fig-
ure 6B) was significantly increased to promoter regions of genes
encoding insulin/IGF signaling proteins such as IGF2, IRS1,
IRS2, and AKT2 after chronic treatment with rapamycin. In-
terestingly, these are the same set of genes that were decreased
by rapamycin (Figure 2C) and increased in YY1-deficient skeletal
muscle (Figure 4C), providing a possible mechanism of tran-
scriptional repression. Pc2 is part of the PRC1 polycomb re-
pressor complex that is sequentially recruited to chromatin
promoter regions after the PRC2 complex, which contains the
methyltransferase Ezh2 and catalyzes trimethylation of H3K27,
an epigenetically repressive histone marker (Hansen et al.,
2008; Kagey et al., 2003; Kuzmichev et al., 2002; Levine et al.,
2004). In fact, Pc2 contains a chromodomain that specifically
interacts with trimethylated H3K27 (Bernstein et al., 2006). In
order to determine if recruitment of YY1 and Pc2 to the pro-
moters of insulin/IGF signaling genes correlated with increases
in H3K27 trimethylation, we performed ChIP analysis using anti-
bodies that specifically recognize this histone modification.
Consistent with recruitment of Pc2, the level of H3K27 trime-
thylation was significantly increased at the promoters of
insulin/IGF signaling genes from skeletal muscle of mice chron-
ically treated with rapamycin (Figure 6C). As a control, H3K27 tri-
methylation at the smooth actin promoter did not change upon
rapamycin treatment (Figure 6D). These results indicate that
upon rapamycin treatment, YY1 and Pc2 are directly recruited
to the promoters of insulin/IGF signaling genes, increasing the
level of H3K27 trimethylation.
AB
C
D
Figure 6. Rapamycin Induces Recruitment
of YY1 and Pc2 to Promoters of Insulin/IGF
Signaling Genes that Are Associated with
H3K27 Trimethylation
(A–D) Mice were treated with vehicle or 2.5 mg/kg
rapamycin for 14 days. ChIP was performed in
whole tissue extracts from skeletal muscle of refed
mice using specific antibodies for YY1 (A), Pc2 (B),
and H3K27 trimethylation (C and D). All values are
presented as mean ± SEM, n = 4, *p < 0.05. IGF2
neg is a negative control in the Igf2 gene promoter,
which does not contain YY1 binding sites.
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the Polycomb Proteins Pc2 and Ezh2
The increase in H3K27 trimethylation by rapamycin treatment at
insulin/IGF signaling gene promoters containing YY1 binding
sites suggested that the methyltransferase Ezh2 might be
involved in the repression of these genes.We therefore assessed
the presence of Ezh2 at these promoters using ChIP analysis on
skeletal muscle of vehicle- or rapamycin-treated mice. Figure 7A
shows that Ezh2 was detected at the promoters of insulin/IGF
signaling genes, but this enrichment was not sensitive to
rapamycin treatment. Consistent with the presence of Ezh2 at
these promoters, YY1 interacted with Ezh2 in a rapamycin-
independent manner (Figure 7B), suggesting that mechanisms
other than increases in Ezh2methyltransferase occupancymight
control the levels of H3K27 trimethylation at promoters of these
genes upon rapamycin treatment. Finally, to determine the con-
tribution of the PRC1 and PRC2 polycomb protein complexes to
the YY1-dependent suppression on insulin/IGF signaling genes,Cell Metabolism 15, 505–we depleted C2C12 cells of Pc2 or Ezh2
using specific shRNA lentiviral constructs
against these proteins (Figure S7). These
stable cell lines were used to express the
different YY1 alleles, including wild-type
and phospho mutants (Figure 7C). As ex-
pected, in shRNA control cells, YY1-AA
exhibited strong repression of insulin/IGF
genes. This repression, however, was
completely blunted in cells depleted of
Pc2 or Ezh2. Interestingly, the degree of
derepression caused by Pc2 or Ezh2
depletion was slightly different within the
genes analyzed, suggesting that some
specific factors might contribute to
these effects. A similar gene expression
pattern, although less pronounced, was
also observed using YY1 wild-type,
whereas the YY1-DD mutant did not
affect the gene expression. These data
indicate that suppression of insulin/IGF
signaling genes driven by YY1 depends
on Pc2 and Ezh2, members of the PRC1
and PRC2 polycomb complexes, respec-
tively. These results also suggest that the
recruitment of Pc2 upon rapamycin treat-
ment could account for the transcriptional
suppression effects of this drug. Further-more, the Pc2 enrichment at YY1 binding sites of insulin/IGF
signaling promoter genes might be necessary for Ezh2 to
increase the levels of the transcriptional repression mark
H3K27 trimethylation.
DISCUSSION
In these studies we have delineated a signaling/transcriptional
pathway by which rapamycin, a drug prescribed in posttrans-
plantation and cancer therapies (Guertin and Sabatini, 2007;
Meric-Bernstam and Gonzalez-Angulo, 2009; Monaco, 2009;
Plas and Thomas, 2009; Sampson, 2009), causes diabetic-like
symptoms and insulin resistance. We show that rapamycin
controls phosphorylation of YY1, allowing for binding of the poly-
comb corepressor Pc2 and recruitment to the chromatin
promoters of insulin/IGF genes. Furthermore, rapamycin treat-
ment leads to an increase in the histone repressive modification
H3K27 trimethylation, which is consistent with this drug517, April 4, 2012 ª2012 Elsevier Inc. 513
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Figure 7. YY1 Suppresses Insulin/IGF Signaling Genes through the Polycomb Proteins Pc2 and Ezh2
(A) Mice were treated with vehicle or 2.5 mg/kg rapamycin for 14 days. ChIP was performed in whole tissue extracts from skeletal muscle of refed mice using
specific antibodies for Ezh2. All values are presented as mean ± SEM, n = 4.
(B) Coimmunoprecipitation and western blot analysis of HEK293 cells treated with vehicle or rapamycin (20 nM) for 2 hr.
(C) shScrambled-, shPc2-, or shEzh2-stable C2C12 myotubes were infected with GFP, wild-type YY1, YY1-AA, or YY1-DD for 48 hr, and gene expression was
measured. All values are presented as mean ± SD, n = 6, *p < 0.05, **p < 0.01, and ***p < 0.001.
(D) Active mTORC1 induces YY1 phosphorylation at T30 and S365, resulting in displacement of Pc2, thereby activating insulin/IGF signaling gene transcription.
Conversely, inactive mTORC1, such as in the presence of rapamycin, results in YY1 dephosphorylation at T30 and S365, permitting recruitment of Pc2 and
consequently the polycomb repressor complex (PRC) to inhibit expression of insulin/IGF signaling genes. The recruitment of YY1 and Pc2 at these promoters
correlates with an increased level of H3K27 trimethylation produced by Ezh2, which is a marker of transcriptional repression. In the absence of YY1, the
suppression on these genes is relieved, leading to their hyperactivation and rapamycin insensitivity. Ac, acetylation; Me, methylation; TAC, transcriptional
activator complex.
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YY1 Regulates Insulin Signaling in Skeletal Musclesuppressing transcription of these genes. The rapamycin-
dependent regulatory role of YY1 is demonstrated using
YY1mKOmice that are protected against the prodiabetic effects
of this drug due to elevated expression of insulin/IGF signaling514 Cell Metabolism 15, 505–517, April 4, 2012 ª2012 Elsevier Inc.genes. Importantly, while rapamycin suppressed these genes
and caused insulin resistance in wild-type mice, YY1mKO mice
were completely refractory to the effects of rapamycin andmain-
tained normal insulin sensitivity. In summary, we propose a
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YY1 Regulates Insulin Signaling in Skeletal Musclemodel in which YY1 mediates rapamycin-induced suppression
of insulin/IGF signaling genes through polycomb proteins and
epigenetic changes that lead to the prodiabetic effects of
rapamycin in vivo (Figure 7D).
Our studies show that skeletal muscle is a key target tissue of
rapamycin and that it mediates, at least in part, the metabolic
dysregulation caused by this drug. This is supported by several
pieces of evidence. First, the clamp experiments show that one
of the major effects of rapamycin on glucose metabolism is
through substantial decreases in glucose disposal, particularly
in skeletal muscle (Figure 1E). Second, skeletal muscle YY1-
and Raptor-deficient mice were entirely protected against
rapamycin-induced whole-body diabetic effects (Figure 3 and
Figure S2D). Despite the fact that our data show that skeletal
muscle is a major tissue targeted by rapamycin and mediates
its metabolic effects, it is likely that other tissues exacerbate
the diabetic symptoms. For example, the liver would contribute
through hepatic insulin resistance to uncontrolled higher rates
of hepatic glucose production, as shown using hyperinsuline-
mic-euglycemic clamps in Figure S1E and as previously sug-
gested in rats (Houde et al., 2010). Unlike other reports (Fraenkel
et al., 2008; Houde et al., 2010), our data do not suggest a defect
in b cell function and insulin secretion upon rapamycin treatment.
The reason for this discrepancy is not clear at this point, but the
use of another animal model might be a possible explanation.
These results have important clinical implications and support
the use of antidiabetic drugs as therapeutic strategies to prevent
diabetes in patients treated with mTOR inhibitors, particularly
drugs that target glucose disposal, such as AMPK activators
(Cuthbertson et al., 2007; Musi et al., 2002).
Whereas the signaling components of the mTOR pathway
have been investigated in considerable detail (Sengupta et al.,
2010b), the transcriptional targets and mechanisms that might
mediate, at least in part, the mTOR metabolic response are not
clear. Recently, several transcription factors including SREBP
and HIF1a have been linked to mTOR activation (Brown et al.,
2007; Du¨vel et al., 2010; Mauvoisin et al., 2007; Peng et al.,
2002; Porstmann et al., 2008), but their involvement in the rapa-
mycin-mediated metabolic dysregulation is unknown. While
these transcription factors might play a role, we have identified
that the transcription factor YY1 in skeletal muscle is controlled
through mTOR activity, and it mediates rapamycin induction of
diabetic-like symptoms. YY1 functions in different transcriptional
protein complexes that activate or repress expression of genes
and participates in different biological processes such as cancer
progression (Castellano et al., 2009; Gordon et al., 2006; Shi
et al., 1997). Our data indicate that the repressive function of
YY1 on insulin/IGF signaling genes promotes the prodiabetic
effects of rapamycin. Among these genes we have found that
Igf1, Igf2, Irs1, and Irs2, as well as Akt1-3, were suppressed by
rapamycin and YY1 (Figures 2C and 4E). Although the extent
to which a specific decrease in these or other proteins within
this pathway can account for the effects of rapamycin on insulin
signaling is not entirely clear, the results suggest that overall
decreases in different insulin signaling components lead to
lower activity of this pathway after insulin stimulation. In fact,
this is consistent with several genetic mouse models in which
several of these components are deleted. For example, skeletal
muscle-specific IRS1/IRS2 knockout mice display decreasedCinsulin-stimulated glucose uptake in muscle and insulin resis-
tance (Long et al., 2011). Furthermore, AKT2-deficient mice
display high plasma insulin, insulin resistance, and impaired
ability to reduce glucose levels, a phenotype attributed to the
impairment of insulin action in skeletal muscle and liver (Cho
et al., 2001; Garofalo et al., 2003). YY1 mediates rapamycin-
induced repression of insulin/IGF signaling genes in skeletal
muscle; thus, the absence of YY1 in this tissue results in in-
creased expression of these genes and loss of rapamycin
repression, causing hyperactivation of insulin/IGF signaling and
insulin sensitivity in YY1mKO mice. The specific and individual
contribution of these or additional genes to insulin signaling
effects is currently unclear. It is possible that upregulation of
IGF proteins could be sufficient to explain protection to insulin
resistance in YY1mKO mice.
Our data show that YY1 plays a pivotal role in the suppression
of insulin/IGF signaling genes in response to rapamycin. Mecha-
nistically, we found that rapamycin induced YY1 dephosphory-
lation and Pc2 corepressor recruitment to the promoters of
these genes. Although YY1 phosphorylation depends on
mTOR activity, it is unclear if mTOR directly phosphorylates
YY1 at T30 and S365 or if other kinases are involved. Consistent
with previous reports that recruitment of Pc2 to promoters of
genes correlates with H3K27 trimethylation (Levine et al.,
2004), we found that rapamycin induced this histone modifica-
tion in skeletal muscle and was associated with decreases in
gene expression. In addition, we detected the presence of the
methyltransferase Ezh2, which catalyzes H3K27 trimethylation,
at promoters of the insulin/IGF signaling genes. In fact, Ezh2
physically interacted with YY1, even though this interaction
was not rapamycin sensitive. Importantly, YY1-mediated sup-
pression on these genes depended on both Pc2 (PRC1 complex)
and Ezh2 (PRC2 complex), suggesting that recruitment of Pc2
might be necessary to increase Ezh2 methyltransferase activity
at these promoters upon rapamycin treatment. To further clarify
this mechanism, it will be necessary to determine the dynamics
of recruitment of YY1 and polycomb protein complexes with
associated enzymatic activities and how they affect different
patterns of histone modifications. These results might have
important implications that go beyond the rapamycin-induced
diabetic-like effects and could provide one of the mechanisms
by which nutrient changes control the epigenetic state of genes
through mTOR pathway and have an impact in metabolic adap-
tation and diseases.
Finally, our results, in addition to supporting the use of antidi-
abetic drugs in patients treated with rapamycin, point toward
the need to consider the prodiabetic effects of this drug in the
context of the life span-promoting effects recently reported
(Harrison et al., 2009) and to evaluate the long-term benefits
and side effects of rapamycin treatment.
EXPERIMENTAL PROCEDURES
Animal Experiments
All experiments and protocols were approved by the Institutional Animal Care
and Use Committees of Dana-Farber Cancer Institute or Beth Israel
Deaconess Medical Center. Six-week-old male C57BL/6 mice were injected
daily intraperitoneally at 5 p.m. with 2.5 mg/kg rapamycin or vehicle (0.1%
DMSO into sterile PBS). The dose of rapamycin was chosen in order to mimic
a typical therapeutic concentration in humans (McAlister et al., 2002). Glucoseell Metabolism 15, 505–517, April 4, 2012 ª2012 Elsevier Inc. 515
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YY1 Regulates Insulin Signaling in Skeletal Muscletolerance test was performed on mice injected with rapamycin for 11 days and
fasted for 12 hr prior to 2 g/kg dextrose intraperitoneal injections. Insulin toler-
ance test was performed on mice injected with rapamycin for 11 days
and fasted for 5 hr prior to 0.6 U/kg insulin intraperitoneal injections. For the
short-term rapamycin treatment, mice were injectedwith 2.5mg/kg rapamycin
or vehicle (0.1% DMSO into sterile PBS), and 12 hr later they were fasted over-
night. Glucose tolerance test was performed in the morning after 12 hr fasting.
HOMA-IR was calculated by the formula (fasted insulin [mU/ml] 3 fasted
glucose [mg/dL])/405.
Generation of YY1mKO Mice
YY1mKO mice were generated by breeding animals harboring a floxed YY1
allele (Affar et al., 2006) with mice that transgenically express CRE recombi-
nase under the control of the myogenin promoter and the MEF2C enhancer
(Li et al., 2005). Wild-type littermates carrying the floxed allele but not CRE
were used as control group. These mice have a mixed background.
Cell Culture and Treatments
C2C12 myoblasts were cultured in DMEM containing 10% fetal bovine serum.
Myoblasts were differentiated in DMEM with 2% horse serum for 72 hr before
infection with the indicated adenoviral constructs. C2C12 myotubes infected
for 48–72 hr were treated with 20 nM rapamycin or vehicle for 16 hr as
indicated.
Chromatin Immunoprecipitation
Mice (n = 4) were treated with vehicle or 2.5 mg/kg rapamycin for 2 weeks and
fasted for 16 hr/refed for 6 hr before sacrifice. Two gastrocnemius muscles of
eachmouse were dissected, cut in pieces, and fixed in 1% formaldehyde/PBS
for 15 min at room temperature. The fixation was quenched by adding a final
concentration of 0.150 M glycine and washed twice in cold PBS. The tissue
was homogenized in cold PBS (containing protease inhibitors) in a motor
pestle. The homogenate was filtered in 100 mm cell strainers and pelleted by
centrifugation at 5 min, 4000 rpm, and 4C. The pellet was resuspended in
500 ml SDS lysis buffer from Millipore EZ-ChIP kit. Samples were sonicated
in Diagenode Bioruptor during five cycles of 5 min with a duty of 30 s on/
30 s off and finally centrifuged for 15 min at 10,000 g. Fifty microliters of
each sample was diluted 1:10 in dilution buffer (from EZ-ChIP kit) and incu-
bated overnight at 4C with 2 mg of the antibodies YY1 (Santa Cruz,
sc-281X), Pc2 (Alexis, ALX-210-570), H3K27me3 (Abcam, ab6002), Ezh2
(Active Motif), and IgG. Immunocomplexes were recovered with Protein A Dy-
nabeads (Invitrogen, Dynabeads 100-02D), and DNA was amplified with
specific primers for the indicated genes by quantitative real-time PCR.
Statistics
Data were analyzed by one-way ANOVA followed by an appropriate post hoc
test for the comparison between two groups. In particular, comparisons
between two groups of mice at different time points were performed by
ANOVA followed by Bonferroni test, whereas comparisons between two
groups of mice at single time points were performed by ANOVA followed by
Tukey test. Significance was defined as p < 0.05. Data are presented
throughout as means ± SD unless otherwise indicated.
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